Compare Harley-Davidson Inc (HOG) vs Incyte Corporation (INCY) Price & Performance

Harley-Davidson (HOG) trades at $26.83, down 0.45% with a bullish technical signal and mixed earnings performance. The stock shows attractive valuation metrics with P/E of 14.86 and P/S of 0.72, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. Recent Q2 2026 earnings beat expectations with $0.75 EPS versus $0.645 expected, though Q1 and Q4 2025 results missed targets. The company maintains a dividend payout with recent $0.1875 declaration.

Outlook remains cautious as revenue declines and margin compression continue, though valuation appears reasonable. Key risks include tariff exposure, competitive pressures, and ongoing revenue contraction. Analyst consensus targets $28.50 with mixed sentiment (27.78% Buy, 61.11% Hold). The stock offers value characteristics but faces fundamental headwinds requiring careful monitoring of turnaround execution.

Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.

The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.